MAMC Pharmacy Series: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for the Pharmacist
This live course will address identification of at-risk patients with MASLD and discuss emerging therapeutic landscape for management.
Target Audience
This activity provides continuing education for pharmacists and pharmacy technicians. A certificate of attendance is available for other attendees.
Learning Objectives
- Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature.
- Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk.
- Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis.
- Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis.
- Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide.
- Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease.
Emily Leaf, PharmD, BC-ADM. Presenter has no relevant financial or non-financial relationship(s) relating to the course content or with ineligible companies to disclose.
Terri Foster, PharmD, MA, CDCES. Presenter has no relevant financial or non-financial relationship(s) relating to the course content or with ineligible companies to disclose.
Disclosure: DHA J-7 staff, planners, authors, faculty, and content reviewers for this educational activity have no relevant financial or non-financial relationship(s) with ineligible companies to disclose.
Available Credit
- 1.00 ACPE-Pharm
UAN: UPDATE
No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacists. This knowledge-based activity will provide a maximum of 1.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity. - 1.00 ACPE-Tech
UAN: UPDATE
No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacy Technicians. This knowledge-based activity will provide a maximum of 1.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity. - 1.00 Attendance
Requirements: CE/CME certificates are awarded to MHS participants who fully complete the activity, successfully submit the evaluation survey, and pass the posttest with a minimum score of 80%. The deadline to claim credit is May 27, 2026.
Access Code: Some activities require an access code to register or claim CE/CME credit. For inquiries regarding the access code or accommodations, please email Dr. Emily Leaf at [email protected].
Accommodations: Please contact the course instructor to inquire about accommodations. For additional accommodation requests and/or technical support, email [email protected].

Facebook
Twitter
LinkedIn
Forward
Facebook
X
LinkedIn
Forward